Press
Kranus Health now raised a total of USD 15 million Series A funding to realize its vision of integrated care in urology
Berlin / Munich / Paris, 2th of October 2023 – Kranus Health, specializing in integrated care within urology, announces that the company is now funded with a Series A round totalling USD 15 million. The round is co-led by new investor SwissHealth Ventures and existing investor, Karista. All other existing investors including HTGF, Wenvest and A Round Capital, have also made significant follow-on investments. The new funds make Kranus Health one of the best-funded digital health startups in
Fund investors
In addition to the Federal Ministry for Economic Affairs and Climate Action (BMWK) and KfW Capital, the investors in our fourth fund (HTGF IV) include 45 companies from a wide range of industries. Medium-sized companies in particular are strongly represented, along with many large corporations and family offices. Here we introduce our strong partners.
Network Partners
Funding Programmes, Other Investors, Network, Research Institutions, Media partner, Universities, Academic institutions, Cooperation partners
Start-up financing
More Than Capital
HTGF is a seed investor for innovative technologies and business models. We are successful in supporting the best founders whose ideas can revolutionize entire industries and improve people’s lives – from the foundation of a start-up to its exit.
Miriam Haerst
Co-Founder / Managing Partner Kumovis GmbH
Invest in the fund
Gain impact to drive your business success
We have been investing in early-stage tech start-ups since 2005. This has enabled us to build up a wide range of expertise in the evaluation of technologies and business models as well as to establish a large international network. Our highly qualified investment team has a wealth of experience in science, engineering, economics, law and humanities. We act as a sparring partner for both our portfolio companies and our fund investors.
A
Press
HTGF portfolio company AYOXXA Biosystems wins new investors to close a € 9,0m Series B round
AYOXXA Biosystems GmbH, an international biotechnology company, completed a € 9,0m Series B financing round by the end of June 2014. All of the company’s existing investors (High-Tech Gründerfonds, KFW, NRW.BANK, Wellington Partners Venture Capital and private investors) took part, along with new investors b-to-v Partners AG, Creathor Venture and HR Ventures. In addition several private investors from the US and Europe, including AYOXXA employees and two of Qiagen’s founders, joined this
Press
Heliatek receives US$ 27 million to continue development of organic solar cells
Heliatek GmbH, a pioneer in the field of organic solar cells, is receiving US$ 27 million (€ 18 million) in a second round of financing under the lead of the pan-European venture capital firm Wellington Partners. Also participating in this round are the industrial investor Bosch and the corporate venture capital investors RWE Innogy Ventures and BASF Venture Capital, the High-Tech-Gründerfonds, eCAPITAL entrepreneurial Partners AG, the Technologiegründerfonds Sachsen Start-up GmbH & Co.
Press
Humedics closes 6.3 million € financing round
Cash inflow enables for commercialization of the LiMAx test
Berlin, Germany, November 10, 2014 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced the closing of a Series C financing round totaling more than 6.3 million Euro. Humedics’ business model, products and company development has attracted new international investors that will join the current private and public investors.
The fin
Press
kaufDA acquires MeinProspekt
By acquiring MeinProspekt, kaufDA expands its reach and offerings as the retail industry's leading advertising partner for local digital brochures in Germany.
Today, consumer information portal kaufDA (www.kaufda.de) announced the acquisition of 100% of the shares of the Munich company MeinProspekt (www.meinprospekt.de). kaufDA, an enterprise of the Berlin-based Bonial International Group (www.bonial.com), thereby expands its leading position regarding mobile, location-based digital catalogs
Press
ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer
ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the round and were joined by BPI France, Schroder Adveq and the German High-Tech Gründerfonds (HTGF).
Markus L.E. Ewert, PhD, MBA has joined the company as Chief Executive Officer. M
Press
Capital for Recycling of High-Tech Composite Materials
saperatec GmbH, an independent recycling specialist for all types of high-tech com-posite materials, is receiving seed financing in the amount of 3.3 million € from an investor consortium consisting of eCapital entrepreneurial Partners AG, the NRW.BANK, the Business Angel Oliver F. Gosemann as well as the investors of the first round Gründerfonds Bielefeld-Ostwestfalen and the High-Tech Gründerfonds. Amongst other things, the company will use the financial means to build a modular large demo
Press
Investors Realize exit VIA Trade Sale of Portfolio Company Corimmun GmbH
Following the sale of their portfolio company CorImmun GmbH to Janssen-Cilag for an undisclosed upfront payment and a contingent future clinical milestone payment, Corimmun’s investors led by MIG have realized an important return on investment.
CorImmun’s lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical studies to improve heart function by decreasing autoimmune, beta 1 receptor-s
Press
Subitec GmbH raises 4.5 m euros in second round financing
Subitec GmbH, a manufacturer of fully automated algae photobioreactors, hascloseda second round of financing. The CleantechFonds of eCAPITAL entrepreneurial Partners AG, Fraunhofer Venture, High-Tech Gründerfonds (HTGF) [High-Tech Start-Up Fund] and KfWBankengruppe’s ERP-Startfonds [ERP Start Fund] participated in the capital increase. Subitec funds to the amount of 4.5 m euros will accrue in this round of financing. The raised capital is to be used mainly for launching bioreactors on the int
Press
Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment
Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life science and technology investors co-led by Boehringer Ingelheim Venture Fund and Kurma Partners and joined by Idinvest Partners, High-Tech Gründerfonds (HTGF), coparion, and Creathor Ventures.
Tacalyx, a spin-
Press
qLearning launches new online platform allowing users to create their own study materials
With the support of its latest investor, High-Tech Gründerfonds (HTGF), qLearning has launched an online platform that enables students and teachers of any discipline to create and share their own study materials. The platform is designed to complement qLearning’s popular mobile app, which already boasts a user base of more than 80,000 students. It also ensures the company keeps up with the ever-evolving student demand for practical learning tools. The investment by HTGF completes this year
Press
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of